Digital Therapeutics Market Outlook 2026–2034: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for Prescription Digital Therapeutics, Remote Patient and Therapeutic Monitoring, Virtual Chronic Care Programmes, Medicare and DiGA Reimbursement — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how digital therapeutics and remote monitoring — software treatments authorised as medical devices, connected sensors that stream physiological and therapeutic data to clinicians, and virtual programmes that manage diabetes, musculoskeletal pain, hypertension, mental health and other chronic conditions between visits — will reshape chronic disease management over the next eight years as payment pathways open and tighten at the same time. The reimbursement precedents are now real. Medicare's digital mental health treatment codes G0552–G0554 took effect in January 2025, were extended to FDA-cleared ADHD devices in the CY 2026 Physician Fee Schedule finalised on 31 October 2025, and now cover nine FDA-cleared products including Big Health's SleepioRx and DaylightRx, Otsuka and Click Therapeutics' Rejoyn and Click's CT-132 for episodic migraine, authorised in April 2025. New remote patient and therapeutic monitoring codes 99445, 99470, 98984, 98985 and 98979 pay from 1 January 2026 for fewer than 16 days of data and fewer than 20 minutes of management a month. Germany's DiGA pathway listed 59 applications and passed nearly one million patient uses by the end of 2024. Capital has returned: Hinge Health, with USD 432 million trailing revenue, and Omada Health, with 2024 revenue of USD 170 million up 38%, completed the first digital health IPOs since 2021 in mid-2025, and Big Health raised USD 23.7 million in February 2026 from .406 Ventures, AlleyCorp and CVS Health Ventures. The counterweight arrived on 14 July 2026, when the CY 2027 proposed rule set out to restrict remote monitoring to practice-employed staff, require an initiating visit, revalue device payments and consider bundling the codes into four G-codes. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2034.

It is a focused 106-page decision brief for payers, health systems and provider groups, pharmaceutical and medical device companies, digital health developers, employers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which product categories and conditions gain durable reimbursement, how evidence, payment rules and integration into care set the pace, and who captures value as chronic disease management moves between visits.

Digital chronic disease management has three layers. Digital therapeutics are software treatments reviewed as medical devices: cognitive behavioural therapy programmes for insomnia, anxiety, depression and ADHD (SleepioRx, DaylightRx, Rejoyn, EndeavorRx), a migraine prevention programme (CT-132) and gastrointestinal, fibromyalgia and substance-use programmes, prescribed by a clinician and paid, in the United States, under Medicare's digital mental health treatment codes and, in Germany, under the DiGA pathway. Remote monitoring is a service: connected blood-pressure cuffs, glucose monitors, scales, pulse oximeters and musculoskeletal sensors transmit data to a practice, whose staff review it and manage treatment under RPM and RTM codes. Virtual chronic care programmes — Hinge Health for musculoskeletal pain, Omada for diabetes prevention and cardiometabolic care, Virta for diabetes reversal, Teladoc and Livongo heritage programmes — bundle coaching, devices and software and sell to employers and payers on enrolment and outcomes.

The evidence and payment base has broadened since 2024. The FDA has cleared nine digital mental health treatments now covered by Medicare; CMS finalised ADHD coverage for 2026 and asked for comment on gastrointestinal, sleep and fibromyalgia categories; the 2026 CPT set added RPM codes 99445 and 99470 and RTM codes 98984, 98985 and 98979 so that fewer than 16 days of data and fewer than 20 minutes of management can be billed; Germany's DiGA passed nearly one million uses with over two-thirds of provisional listings made permanent; and Hinge Health reported revenue of USD 139 million in its first public quarter, up 55%, at an 83% adjusted gross margin, while Omada reported USD 61 million, up 49%, with 2,000 customers.

The constraints are payment stability, evidence, integration and economics. Medicare's G0552 remains contractor-priced with no national rate and low claims volume; the CY 2027 proposed rule would confine remote monitoring to practice-employed staff, require an initiating visit, revalue devices and consider bundling codes, which threatens the outsourced monitoring model; prescription digital therapeutics have struggled commercially, as Pear Therapeutics' 2023 bankruptcy showed; and programmes must prove outcomes and savings to employers and payers that are consolidating vendors. The decade's question is whether payment settles into stable national rates and standard benefits before developers run out of runway.

The digital therapeutics market as defined in this brief — FDA-authorised and DiGA-listed digital therapeutics, remote physiological and therapeutic monitoring services and the connected devices used in chronic disease programmes, and virtual chronic care programmes sold to payers and employers, excluding general telehealth visits, electronic health records, consumer wellness applications and diabetes supplies sold outside a programme — is estimated at USD 9–12 billion in 2026, led by virtual chronic care providers such as Hinge Health, Omada Health, Virta Health and Teladoc Health, by Medicare and commercial remote monitoring, and by prescription digital therapeutics and DiGA in early reimbursement. Meticulous Next™ expects it to reach USD 38–52 billion by 2034, an indicative CAGR of 19–21%. Growth is driven by national Medicare rates and new device categories for digital therapeutics, by remote monitoring under stable post-2027 rules, by employer and payer standard benefits for virtual chronic care, by pharma companion programmes around obesity, diabetes and mental health drugs, and by guideline inclusion. The forecast is sensitive to the final CY 2027 rule, to G0552 pricing and to employer purchasing. The United States leads through Medicare and employer markets; Germany leads Europe through DiGA, with France and Belgium following; the United Kingdom, Japan and South Korea add approval pathways; diabetes, musculoskeletal, cardiometabolic and mental health conditions lead adoption.

The base case assumes a CY 2027 final rule that tightens but preserves remote monitoring, national G0552 pricing by 2028, two new Medicare digital therapeutic categories by 2028 and continued employer adoption. An accelerated case adds a softened 2027 rule, rapid category expansion and guideline inclusion by 2028, bringing the inflection to 2028 and lifting the 2034 value to the top of the range. A delayed case assumes the proposed remote monitoring restrictions finalised in full, continued contractor pricing for digital therapeutics and employer cutbacks, slowing growth to the bottom of the range.

Growth drivers

• Medicare payment pathways: DMHT codes since January 2025, extended to ADHD for 2026; RPM and RTM codes for fewer than 16 days and 20 minutes from 1 January 2026.
• Commercial proof: Hinge Health USD 432 million trailing revenue and 83% adjusted gross margin; Omada 750,000 enrolled members and 49% growth; both public since 2025.
• Chronic disease burden and workforce shortage pushing care between visits; Consolidated Appropriations Act 2026 telehealth flexibilities through 2027.
• European precedent: DiGA with 59 listed applications and nearly one million uses, Digital Act of March 2024.

Enablers

• FDA special controls and device categories (882.5801, 882.5803 and proposed 876.5960, 882.5705, 882.5804) that define reimbursable classes.
• Connected devices and over-the-counter sensors feeding programmes and monitoring.
• Integration with primary care management, behavioural health integration and Medicare Advantage.
• Capital: 2025 IPOs, Big Health's USD 23.7 million strategic round with CVS Health Ventures and Blue Venture Fund.

Restraints and barriers

• CY 2027 proposed restrictions on remote monitoring — in-house staff only, initiating visit, device revaluation and possible code bundling.
• Contractor pricing and low claims volume for G0552; no national rate.
• Commercial failures of prescription digital therapeutics, including Pear Therapeutics' 2023 bankruptcy.
• Employer and payer vendor consolidation and demands for outcomes and savings evidence.

Five converging forces will determine whether, and how fast, digital therapeutics and remote monitoring become the default for chronic disease management: (1) Medicare payment rules for digital therapeutics and remote monitoring; (2) commercial payer and employer coverage of virtual chronic care; (3) evidence and guideline inclusion; (4) integration into practice workflows and care management; and (5) pharma and device companion programmes. The brief assesses each force for direction, speed and confidence.

The key players operating in digital therapeutics and remote monitoring include Hinge Health, Inc., Omada Health, Inc., Virta Health Corp., Teladoc Health, Inc., Big Health, Inc., Click Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Akili, Inc., DarioHealth Corp., Welldoc, Inc., Sword Health, Inc., Kaia Health GmbH, Lark Technologies, Inc., Twin Health, Inc., Vida Health, Inc., Dexcom, Inc., Abbott Laboratories, Medtronic plc, Withings SA, iRhythm Technologies, Inc., Biofourmis Inc., Cadence Solutions, Inc., Optimize Health, Inc., Health Recovery Solutions, Inc., CareSimple Inc., Validic, Inc., GAIA AG, Kaia Health, HelloBetter (GET.ON Institut GmbH), Sidekick Health, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, CVS Health Corporation, UnitedHealth Group Incorporated, Elevance Health, Inc., Cigna Group, Mayo Clinic, Kaiser Permanente, the Centers for Medicare & Medicaid Services, the Federal Institute for Drugs and Medical Devices (BfArM), .406 Ventures, AlleyCorp and CVS Health Ventures. The brief profiles representative players in each archetype and assesses which are positioned to make between-visit care the default.

The competitive landscape is forming around six archetypes. Virtual chronic care providers at scale. Prescription digital therapeutic developers. Remote monitoring platforms and service vendors. Connected device and sensor makers. Pharma and payer sponsors. Health systems, regulators and investors. Competitive intensity is high in 2026 after years of fragmentation and is expected to consolidate sharply around reimbursed categories and employer contracts through 2029.

Where value migrates.

In 2026 value sits in scaled virtual chronic care contracts, outsourced remote monitoring and early prescription digital therapeutic sales. By 2029 it moves to practice-owned monitoring under the 2027 rules, nationally priced digital therapeutic categories, standard employer and payer benefits and pharma companion programmes. By 2034 it settles in scaled virtual care providers, developers with reimbursed products, health systems that own monitoring and the device makers that supply every programme. Outsourced monitoring vendors without a practice-staffed model and applications without reimbursement lose ground.

Capital has returned selectively: the Hinge Health and Omada Health IPOs in 2025, Big Health's USD 23.7 million strategic round with payer-linked investors in February 2026, and reported IPO preparations at Virta Health. Clinical and commercial signals are concentrated in musculoskeletal, cardiometabolic and mental health programmes, with migraine, ADHD, gastrointestinal and sleep categories entering reimbursement. Policy signals point both ways: wider thresholds for 2026 and tighter rules proposed for 2027. The brief tracks four indicators: the final CY 2027 rule, national pricing for G0552, new Medicare digital therapeutic categories and employer renewal rates for virtual chronic care.

The United States leads through Medicare and employer markets; Germany leads Europe through DiGA with France and Belgium following; the United Kingdom, Japan and South Korea add pathways. Diabetes and obesity, musculoskeletal pain, hypertension and heart failure, and insomnia, anxiety, depression and ADHD are the first conditions.